AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Azimuth Capital Management LLC


Share on StockTwits

Azimuth Capital Management LLC increased its holdings in AstraZeneca PLC (NASDAQ:AZN) by 5.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 61,123 shares of the company’s stock after buying an additional 2,899 shares during the period. Azimuth Capital Management LLC’s holdings in AstraZeneca were worth $3,056,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Creative Planning increased its stake in AstraZeneca by 4.6% in the 4th quarter. Creative Planning now owns 67,863 shares of the company’s stock valued at $3,392,000 after buying an additional 2,982 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in AstraZeneca in the 3rd quarter valued at $1,221,000. Koshinski Asset Management Inc. increased its stake in AstraZeneca by 518.9% in the 4th quarter. Koshinski Asset Management Inc. now owns 28,512 shares of the company’s stock valued at $915,000 after buying an additional 23,905 shares during the period. Diversified Trust Co acquired a new position in AstraZeneca in the 4th quarter valued at $647,000. Finally, Cubist Systematic Strategies LLC increased its stake in AstraZeneca by 48.4% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 80,575 shares of the company’s stock valued at $4,416,000 after buying an additional 26,290 shares during the period. 15.57% of the stock is currently owned by institutional investors.

Shares of AstraZeneca stock traded down $0.97 on Tuesday, hitting $49.60. The company’s stock had a trading volume of 923,500 shares, compared to its average volume of 11,384,333. The company has a market capitalization of $130.18 billion, a P/E ratio of 52.87, a price-to-earnings-growth ratio of 1.18 and a beta of 0.55. The company has a quick ratio of 0.76, a current ratio of 0.96 and a debt-to-equity ratio of 1.34. The firm has a fifty day moving average price of $51.16 and a 200-day moving average price of $52.26. AstraZeneca PLC has a 52-week low of $36.15 and a 52-week high of $64.94.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Wednesday, February 10th. The company reported $0.54 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.68 by ($0.14). AstraZeneca had a net margin of 9.65% and a return on equity of 37.23%. As a group, analysts expect that AstraZeneca PLC will post 2 earnings per share for the current year.

The company also recently announced a semi-annual dividend, which will be paid on Monday, March 29th. Shareholders of record on Friday, February 26th will be issued a $0.95 dividend. This represents a yield of 2.7%. This is a positive change from AstraZeneca’s previous semi-annual dividend of $0.45. The ex-dividend date is Thursday, February 25th. AstraZeneca’s dividend payout ratio is 50.29%.

A number of equities analysts have recently weighed in on AZN shares. AlphaValue raised shares of AstraZeneca to a “reduce” rating in a research note on Wednesday, December 30th. Barclays reaffirmed an “overweight” rating on shares of AstraZeneca in a research note on Friday, January 22nd. Morgan Stanley raised shares of AstraZeneca from an “equal weight” rating to an “overweight” rating in a research note on Monday, December 7th. UBS Group reaffirmed a “positive” rating on shares of AstraZeneca in a research note on Monday, December 14th. Finally, Piper Sandler decreased their price objective on shares of AstraZeneca from $179.00 to $175.00 and set an “overweight” rating on the stock in a research report on Sunday, December 13th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $83.80.

AstraZeneca Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases.

Featured Article: What are momentum indicators and what do they show?

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.